HMD launches Dispojekt safety needle syringes to curb Needle Stick Injuries
Hindustan Syringes and Medical Devices (HMD), one of the leading manufacturers of disposable and AutoDisable syringes in the world, has launched Dispojekt single use syringes with safety needle that is designed to reduce prevalence of accidental Needle Stick Injuries (NSIs) among health workers.
“Equipped with a safety shield (SIP Shield), Dispojekt syringe addresses critical concerns of needle stick injuries and reaffirms our commitment as market leader towards excellence in healthcare. It is a great outcome of our ‘Make in India’ resolve as envisioned by Prime Minister Narendra Modi to realize the goal of Viksit Bharat,” said Rajiv Nath, Managing Director, HMD, adding that India is all poised to become a global powerhouse in manufacturing and exporting of medical devices in sync with the spirit of Atmanirbhar Bharat.
The use of safety needles in healthcare settings offer numerous cost benefits. They reduce healthcare worker injuries, lowering costs from potential disease treatment and potential long-term health issues. By minimizing needle stick injuries, they also decrease expenses for post-exposure prophylaxis and associated healthcare costs. Moreover, safety needles mitigate compensation claims, absenteeism, and can lead to lower health insurance premiums, while also reducing product and packaging footprints for cost and environmental savings. They assist in creating a safer and more reliable workplace environment for healthcare workers.
“There is significant headroom for innovation and growth in the medical devices industry and the future of healthcare technology rests on robust R&D. With the disposable syringe market size in India estimated to be over 5 billion units per year and 5-6 billion needles, 80 % of which are in the hands of private sector players. We aim for 60-70 % market share in the next three years, thanks to our innovative Dispojekt,” informed HMD’s Executive Director, Sohail Nath.
He said, “Dispojekt safety needle syringes are going to be the game changer in the global fight against NSIs. We are aiming to initially produce 200 million syringes and needles per annum for which we have invested approximately Rs 70 crore in the first phase.”
Sohail adds, “In the second phase, we will increase the capacity to 300 million pieces per annum by investing another Rs 10 crore to Rs 15 crore.”
